HLS Therapeutics (TSE:HLS) Shares Down 0.3% – Here’s Why

HLS Therapeutics Inc. (TSE:HLS) dropped 0.3% during trading on Friday . The stock traded as low as C$3.33 and last traded at C$3.64. Approximately 59,500 shares were traded during mid-day trading, an increase of 111% from the average daily volume of 28,252 shares. The stock had previously closed at C$3.65.

Analyst Ratings Changes

Separately, Raymond James boosted their target price on HLS Therapeutics from C$4.00 to C$5.00 in a research report on Friday, November 22nd.

HLS Therapeutics Trading Down 0.3 %

The company has a debt-to-equity ratio of 100.44, a current ratio of 2.02 and a quick ratio of 1.01. The stock’s 50-day moving average is C$3.55 and its two-hundred day moving average is C$3.44. The company has a market cap of C$115.72 million, a P/E ratio of -3.60 and a beta of 1.07.

About HLS Therapeutics

HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company’s product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease.